Waning humoral immune response to the BNT162b2 vaccine in heart transplant recipients over 6 months

Yael Peled; Eilon Ram; Michal Mandelboim; Jacob Lavee; Leonid Sternik; Amit Segev; Anat Wieder-Finesod; Rebecca Halperin; Victoria Indenbaum; Itzchak Levy; Jignesh Patel; Ehud Raanani; Yaniv Lustig; Galia Rahav

doi:10.1111/ajt.16998

Waning humoral immune response to the BNT162b2 vaccine in heart transplant recipients over 6 months

Am J Transplant. 2022 Jul;22(7):1931-1932. doi: 10.1111/ajt.16998. Epub 2022 Mar 1.

Authors

Yael Peled^{1

2}, Eilon Ram^{1

2}, Michal Mandelboim^{2

3}, Jacob Lavee^{1

2}, Leonid Sternik^{1

2}, Amit Segev^{1

2}, Anat Wieder-Finesod^{2

4}, Rebecca Halperin⁴, Victoria Indenbaum⁴, Itzchak Levy^{2

4}, Jignesh Patel⁵, Ehud Raanani^{1

2}, Yaniv Lustig^{2

3}, Galia Rahav^{2

4}

Affiliations

¹ Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Tel Hashomer, Israel.
² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Central Virology Laboratory, Public Health Services, Ministry of Health, Sheba Medical Center, Tel Hashomer, Israel.
⁴ Infectious Disease Unit, Sheba Medical Center, Tel Hashomer, Israel.
⁵ David Geffen School of Medicine at the University of California, Cedars-Sinai Heart Institute, Los Angeles, California, USA.

No abstract available

Keywords: clinical research/practice; heart transplantation/cardiology; infection and infectious agents-viral; infection and infectious agents-viral: SARS-CoV-2/COVID-19.

Publication types

Letter

MeSH terms

Antibodies, Viral
BNT162 Vaccine
Heart Transplantation*
Humans
Immunity, Humoral
Influenza Vaccines*
Transplant Recipients

Substances

Antibodies, Viral
Influenza Vaccines
BNT162 Vaccine